 |
|
|
| |
Cabotegravir long-acting protects macaques against repeated penile SHIV exposures
|
| |
| |
The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention
"Three monthly IM injections (50 mg/kg) to maintain CAB levels in plasma above 4x PA-IC90......Challenge once-weekly (12 weeks)"
Cabotegravir long-acting (CAB LA) is an investigational HIV integrase inhibitor that is currently in clinical development as a PrEP agent. In pre-clinical proof-of-concept studies in macaques, CAB LA was highly effective against rectal, vaginal, and intravenous infection with simian HIV (SHIV). Penile transmission accounts for nearly one-half of all HIV infections globally, and whether CAB LA can also protect against this important route has not been adequately addressed primarily due to the lack of a validated in vivo model of penile transmission. Here we used a novel macaque model of repeated penile SHIV exposures to investigate the efficacy of CAB LA against penile infection. These data support advancement of CAB LA as a PrEP candidate for men.
Reported by Jules Levin
CROI 2018 March 4-7 Boston, MA
Charles Dobard1, Natalia Makarova1, Kenji Nishiura1, Mara Sterling1, Chuong Dinh1, James Mitchell1, David Garber1, William Spreen2, Walid Heneine1, and J. Gerardo Garcia-Lerma1
1Centers for Disease Control and Prevention, Atlanta, GA, US
WEBCAST: http://www.croiwebcasts.org/console/player/37185?mediaType=slideVideo&&crd_fl=1&ssmsrq=1520686020078&ctms=5000&csmsrq=986
|
| |
|
|
|
|
|
